Ironwood Tumor Board 2025

Ironwood Tumor Board 2025 - 2/17/2025

February 17, 2025 – 8:00 AM Other

Overall Activity Objectives:

- 1 Utilize the AJCC 8th Edition staging more consistently
- 2 Follow evidence-based guidelines and individual patient factors in order to make better surgical and treatment decisions
- 3 Minimize side effects and complications of therapy
- 4 Optimize oncological and cosmetic outcomes

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Ironwood Cancer and Research Center The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Rashmi Vaidya, MD	Activity Director	Honoraria-Novartis Corporation Pharmaceuticals (Relationship has ended) - 11/27/2024
Joseph Di Como, MD	Faculty	Nothing to disclose - 11/07/2024

